subscribeSubscribe
Chugai obtains Japanese approval for FoundationOne Liquid CDx Genomic Profile

Chugai obtains Japanese approval for FoundationOne Liquid CDx Genomic Profile
PHARMABIZ
27 May 2023
Share Share
Novartis announces MET inhibitor Tabrecta™ approved in Japan METex14

Novartis announces MET inhibitor Tabrecta™ approved in Japan METex14
PRESS RELEASE
29 Jun 2020
Share Share
Chugai gets Japanese approval for expanded use of FoundationOne CDx Genomic

Chugai gets Japanese approval for expanded use of FoundationOne CDx Genomic
PHARMABIZ
29 May 2020
Share Share
Novartis leans into digital for mid-pandemic lung cancer launch

Novartis leans into digital for mid-pandemic lung cancer launch
Carly Helfand FIERCEPHARMA
11 May 2020
Share Share
FDA okays Tabrecta, adds indication for Farxiga

FDA okays Tabrecta, adds indication for Farxiga
Renee Matthews RAPS
09 May 2020
Share Share
FDA approval for Tabrecta in metastatic non-small cell lung cancer with METex14

FDA approval for Tabrecta in metastatic non-small cell lung cancer with METex14
PHARMAFILE
08 May 2020
Share Share
FDA approval for Tabrecta in metastatic non-small cell lung cancer with METex14

FDA approval for Tabrecta in metastatic non-small cell lung cancer with METex14
PHARMAFILE
07 May 2020
Share Share
Novartis lands capmatinib approval, giving them a second blockbuster from Incyte

Novartis lands capmatinib approval, giving them a second blockbuster from Incyte
ENDPTS
07 May 2020
Share Share
Novartis beats out Merck KGaA with lung cancer drug Tabrecta

Novartis beats out Merck KGaA with lung cancer drug Tabrecta
Carly Helfand FIERCE PHARMA
07 May 2020
Share Share
Incyte Announces FDA Approval of Tabrecta™ (capmatinib) for the Treatment

Incyte Announces FDA Approval of Tabrecta™ (capmatinib) for the Treatment
BUSINESSWIRE
06 May 2020
Share Share